Rohto Pharmaceutical Co.,Ltd.
4527.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | ¥74,066,000 | ¥75,839,000 | ¥77,161,000 | ¥61,713,000 |
| Short-Term Investments | ¥4,178,000 | ¥0 | ¥0 | ¥0 |
| Receivables | ¥71,799,000 | ¥44,691,000 | ¥69,880,000 | ¥54,070,000 |
| Inventory | ¥63,120,000 | ¥63,163,000 | ¥61,580,000 | ¥61,255,000 |
| Other Curr. Assets | ¥9,065,000 | ¥31,384,000 | ¥9,258,000 | ¥28,407,000 |
| Total Curr. Assets | ¥222,228,000 | ¥215,077,000 | ¥217,879,000 | ¥205,445,000 |
| Property Plant & Equip (Net) | ¥88,859,000 | ¥88,364,000 | ¥90,451,000 | ¥86,824,000 |
| Goodwill | ¥33,022,000 | ¥32,932,000 | ¥47,494,000 | ¥46,017,000 |
| Intangibles | ¥34,791,000 | ¥34,720,000 | ¥8,575,000 | ¥8,539,000 |
| Long-Term Investments | ¥49,495,000 | ¥38,909,000 | ¥46,427,000 | ¥48,077,000 |
| Tax Assets | ¥0 | ¥0 | ¥3,975,000 | ¥0 |
| Other NC Assets | ¥11,506,000 | ¥18,324,000 | ¥7,074,000 | ¥8,957,000 |
| Total NC Assets | ¥217,673,000 | ¥213,249,000 | ¥203,996,000 | ¥198,414,000 |
| Other Assets | ¥3,000 | ¥0 | ¥0 | ¥0 |
| Total Assets | ¥439,904,000 | ¥428,326,000 | ¥421,875,000 | ¥403,859,000 |
| Liabilities | – | – | – | – |
| Payables | ¥22,183,000 | ¥24,098,000 | ¥22,056,000 | ¥18,306,000 |
| Short-Term Debt | ¥20,142,000 | ¥6,843,000 | ¥7,035,000 | ¥21,018,000 |
| Tax Payable | ¥5,801,000 | ¥0 | ¥0 | ¥0 |
| Deferred Revenue | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Curr. Liab. | ¥54,151,000 | ¥29,744,000 | ¥55,316,000 | ¥38,840,000 |
| Total Curr. Liab. | ¥102,277,000 | ¥84,839,000 | ¥94,608,000 | ¥106,672,000 |
| LT Debt | ¥26,939,000 | ¥42,039,000 | ¥43,188,000 | ¥17,788,000 |
| Deferred Rev, NC | ¥0 | ¥0 | ¥0 | ¥0 |
| Deferred Tax Liab, NC | ¥0 | ¥0 | ¥2,081,000 | ¥0 |
| Other NC Liab. | ¥18,422,000 | ¥17,305,000 | ¥3,370,000 | ¥12,223,000 |
| Total NC Liab. | ¥45,361,000 | ¥59,344,000 | ¥55,825,000 | ¥30,011,000 |
| Other Liabilities | ¥0 | ¥0 | ¥0 | ¥0 |
| Cap. Leases | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Liabilities | ¥147,638,000 | ¥144,183,000 | ¥150,433,000 | ¥136,683,000 |
| Equity | – | – | – | – |
| Pref Stock | ¥0 | ¥0 | ¥0 | ¥0 |
| Common Stock | ¥6,504,000 | ¥6,504,000 | ¥6,504,000 | ¥6,504,000 |
| Retained Earnings | ¥244,754,000 | ¥238,871,000 | ¥228,442,000 | ¥221,983,000 |
| AOCI | ¥33,867,000 | ¥31,303,000 | ¥35,086,000 | ¥32,520,000 |
| Other Equity | ¥2,000 | ¥0 | ¥2,000 | ¥3,000 |
| Total Equity | ¥275,186,000 | ¥266,739,000 | ¥260,095,000 | ¥256,071,000 |
| Supplemental Information | – | – | – | – |
| Minority Interest | ¥17,080,000 | ¥17,404,000 | ¥11,345,000 | ¥11,108,000 |
| Total Liab. & Tot. Equity | ¥439,904,000 | ¥428,326,000 | ¥421,875,000 | ¥403,859,000 |
| Net Debt | -¥26,985,000 | -¥26,957,000 | -¥26,938,000 | -¥22,907,000 |